When will midostaurin be launched in China?

Midostaurin, as a therapeutic drug for FLT3 mutation-positive acute myeloid leukemia, has been widely recognized overseas for its efficacy and safety. However, for Chinese patients, one of the questions they are most concerned about is: when will midostaurin be available in China?

1. Current listing status

As of now, midostaurin is not yet available in China. This means that if Chinese patients want to use this drug, they need to purchase it through overseas channels, which undoubtedly increases the difficulty and cost of treatment.

2. Overseas listing situation

Currently, midostaurin is already on the market overseas, and there are multiple versions available, including original drugs and economical generic drugs at different prices. For example, the European version of the original drug is more expensive, with a box of 25mg*112 pills priced at more than 120,000 yuan. In contrast, the Indian version of the original drug is more affordable, with the same specifications priced at only more than 3,000 yuan. In addition, India's BDR Pharmaceuticals has also launched a lower-priced generic drug, priced at about more than 2,000 yuan, providing patients with more choices.

3. Prospects for listing in China

Although there is currently no definite news on when Midostaurin will be launched in China, with the continuous opening and progress of China's medical market and the growing demand of patients for innovative drugs, we believe that we are expected to see Midostaurin launched in China in the near future.

4. Patients’ expectations and suggestions

For leukemia patients in China, they are eagerly looking forward to midostaurin being launched in China as soon as possible, thereby reducing the economic burden of treatment and improving treatment effectiveness. At the same time, it is recommended that relevant departments speed up the approval process and promote the introduction and marketing of innovative drugs to meet the actual needs of patients.

In general, although midostaurin is not currently available in China, with the improvement of the medical environment and the promotion of patient demand, I believe this day will come as soon as possible. During this period, patients and their families can learn about relevant information about overseas drug purchases through formal channels to ensure the safety and effectiveness of treatment.